Prostatitis is the inflammation of the prostate that may be caused by infection, chronic pelvic pain syndrome or asymptomatic prostate inflammation.
Prominent features are genitourinary, pelvic or rectal pain and lower urinary tract symptoms, eg urinary frequency, urgency, hesitancy, weak stream and straining on urination, dysuria, pain that increased with urination.
Grabe M, Bartoletti R, Bjerklund Johansen TE, et al. Guidelines on urological infections. European Association of Urology. http://uroweb.org. Mar 2015. Accessed 28 Oct 2015.
Canadian guidelines on sexually transmitted infections. Prostatitis. Public Health Agency of Canada. http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-4-5-eng.php. 02 Jan 2013.
Coker TJ, Dierfeldt DM. Acute bacterial prostatitis: diagnosis and management. Am Fam Physician. 2016 Jan 15;93(2):114-120. http://www.aafp.org/afp/2016/0115/p114.html.
Dickson G. Prostatitis-diagnosis and treatment. Aust Fam Physician. 2013 Apr;42(4):216-219. http://www.racgp.org.au/download/Documents/AFP/2013/April/201304dickson.pdf. PMID: 23550248
Kaplan SA. Benign prostatic hyperplasia and prostatitis. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders; 2016. https://www.clinicalkey.com/#!/content/book/3-s2.0-B978145575017700129X. Accessed 18 Jan 2016:830-833.
Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis. 2010 Jun 15;50(12):1641-1652. doi: 10.1086/652861. PMID: 20459324
Meyrier A, Fekete T. Acute bacterial prostatitis. UpToDate. http://www.uptodate.com/contents/acute-bacterial-prostatitis. 03 Dec 2015.
Nickel JC. Prostatitis. Canadian Urological Association Journal. 2011 Oct;5(5):306-315. doi: 10.5489/cuaj.11211.
Rees J, Abrahams M, Doble A, Cooper A; Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015 Oct;116(4):509-525. doi: 10.1111/bju.13101. Accessed 09 Aug 2016. PMID: 25711488
Sharp VJ, Takacs EB, Powell CR. Prostatitis: diagnosis and treatment. Am Fam Physician. 2010 Aug 15;82(4):397-406. http://www.aafp.org/afp/2010/0815/p397.html. PMID: 20704171
Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.